Dennis Verzijl
Overview
Explore the profile of Dennis Verzijl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
690
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hiemstra I, Santegoets K, Janmaat M, De Goeij B, Ten Hagen W, van Dooremalen S, et al.
EBioMedicine
. 2023 Jun;
93:104663.
PMID: 37379657
Background: HexaBody®-CD38 (GEN3014) is a hexamerization-enhanced human IgG1 that binds CD38 with high affinity. The E430G mutation in its Fc domain facilitates the natural process of antibody hexamer formation upon...
2.
Kemper K, Gielen E, Boross P, Houtkamp M, Plantinga T, de Poot S, et al.
Life Sci Alliance
. 2022 Oct;
5(11).
PMID: 36271507
CD3 bispecific antibodies (bsAbs) show great promise as anticancer therapeutics. Here, we show in-depth mechanistic studies of a CD3 bsAb in solid cancer, using DuoBody-CD3x5T4. Cross-linking T cells with tumor...
3.
Muik A, Adams 3rd H, Gieseke F, Altintas I, Schoedel K, Blum J, et al.
J Immunother Cancer
. 2022 Jun;
10(6).
PMID: 35688554
Background: Despite the preclinical promise of CD40 and 4-1BB as immuno-oncology targets, clinical efforts evaluating CD40 and 4-1BB agonists as monotherapy have found limited success. DuoBody-CD40×4-1BB (GEN1042/BNT312) is a novel...
4.
van Aalen E, Wouters S, Verzijl D, Merkx M
Anal Chem
. 2022 Apr;
94(17):6548-6556.
PMID: 35438976
Early diagnosis of cancer is essential for the efficacy of treatment. Our group recently developed RAPPID, a bioluminescent immunoassay platform capable of measuring a wide panel of biomarkers directly in...
5.
Muik A, Altintas I, Gieseke F, Schoedel K, Burm S, Toker A, et al.
Oncoimmunology
. 2022 Feb;
11(1):2030135.
PMID: 35186440
Immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 axis have changed the treatment paradigm for advanced solid tumors; however, many patients experience treatment resistance. In preclinical models 4-1BB co-stimulation synergizes with...
6.
Muik A, Garralda E, Altintas I, Gieseke F, Geva R, Ben-Ami E, et al.
Cancer Discov
. 2022 Feb;
12(5):1248-1265.
PMID: 35176764
Significance: DuoBody-PD-L1×4-1BB (GEN1046) is a first-in-class bispecific immunotherapy with a manageable safety profile and encouraging preclinical and early clinical activity. With its ability to confer clinical benefit in tumors typically...
7.
Richter R, Jochheim-Richter A, Ciuculescu F, Kollar K, Seifried E, Forssmann U, et al.
Stem Cells Dev
. 2014 Apr;
23(16):1959-74.
PMID: 24708339
Mobilization of hematopoietic stem and progenitor cells (HPCs) is induced by treatment with granulocyte-colony stimulating factor, chemotherapy, or irradiation. We observed that these treatments are accompanied by a release of...
8.
Blanchetot C, Verzijl D, Mujic-Delic A, Bosch L, Rem L, Leurs R, et al.
J Biol Chem
. 2013 Jul;
288(35):25173-25182.
PMID: 23836909
Chemokine receptors and their ligands play a prominent role in immune regulation but many have also been implicated in inflammatory diseases such as multiple sclerosis, rheumatoid arthritis, allograft rejection after...
9.
Langemeijer E, Verzijl D, Dekker S, Ijzerman A
Purinergic Signal
. 2012 Oct;
9(1):91-100.
PMID: 23054444
The concept of functional selectivity offers great potential for the development of drugs that selectively activate a specific intracellular signaling pathway. During the last few years, it has become possible...
10.
Gao Z, Verzijl D, Zweemer A, Ye K, Goblyos A, IJzerman A, et al.
Biochem Pharmacol
. 2011 Jul;
82(6):658-68.
PMID: 21718691
Allosteric modulators for the G(i)-coupled A(3) adenosine receptor (AR) are of considerable interest as therapeutic agents and as pharmacological tools to probe various signaling pathways. In this study, we initially...